XIBENOLOL

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C15H25NO2
Molecular Weight	251.3645
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=C(C)C(OCC(O)CNC(C)(C)C)=CC=C1

InChI

InChIKey=RKUQLAPSGZJLGP-UHFFFAOYSA-N

InChI=1S/C15H25NO2/c1-11-7-6-8-14(12(11)2)18-10-13(17)9-16-15(3,4)5/h6-8,13,16-17H,9-10H2,1-5H3

HIDE SMILES / InChI

Molecular Formula	C15H25NO2
Molecular Weight	251.3645
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8021 | https://www.ncbi.nlm.nih.gov/pubmed/6131020 | http://adisinsight.springer.com/drugs/800000135

Xibenolol or D-32 (dl-tert-butylamino-3-(2', 3'-dimethylphenoxy)-2-propanol hydrochloride) is a beta-blocking agent. It has been developing as a hypontesive medicine by Kowa Pharmaceutical and Teikoku Hormone, however development has been discontinued.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adrenergic receptor beta 89 Target ID: CHEMBL2094118 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8021 \| https://www.ncbi.nlm.nih.gov/pubmed/6131020 \| http://adisinsight.springer.com/drugs/800000135	Antagonist 2849

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 575 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6131020 https://www.ncbi.nlm.nih.gov/pubmed/15525 https://www.ncbi.nlm.nih.gov/pubmed/8021	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
[Stereoselective glucuronidation of beta-blocking agents, 1-tert-butylamino-3-(2,3-dimethylphenoxy)-2-propanol (D-32) and propranolol, in animals, in vivo and in vitro].	1986-05	2876088
Stereoselectivity in the metabolism of the beta-adrenergic blocking agent, (+/-)-1-tert-butylamino-3-(2,3-dimethylphenoxy)-2-propanol hydrochloride (xibenolol hydrochloride, D-32), in man.	1985-02	2861914
Effects of beta-adrenoceptor blocking agents of N-tertiary butyl derivatives on maximum upstroke velocity of action potential in guinea-pig papillary muscles.	1983-09	6138715
[Antihypertensive action of adrenergic beta-receptor blockers and its effect on the entire sympathetic outflow in spontaneously hypertensive rats].	1982-12	6131020
Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs.	1981-02	6116195
Analysis of beta-adrenoceptors mediating renin release produced by isoproterenol in conscious dogs.	1980-05	6103674
Effects of beta-adrenoceptor blocking agents, pindolol, alprenolol and practolol on blood pressure and heart rate in conscious renal hypertensive dogs.	1977-01	15525

Patents

Sample Use Guides

In Vivo Use Guide

dogs: 50 mg/kg, p.o. 1 mg/kg per min for 5 min i.v. rats: 2 X 15 or 2 X 50 mg/kg/day p.o.

Route of Administration: Other

In Vitro Use Guide

The effects of xibenolol (D-32) (17.3-100 uM) on action potentials were investigated in isolated guinea-pig papillary muscles.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:06:08 GMT 2025` Edited by `admin` on `Mon Mar 31 18:06:08 GMT 2025`
Record UNII	0871JY946G
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

XIBENOLOL [MI]

Preferred Name

English

XIBENOLOL

Official Name

English

(±)-1-(TERT-BUTYLAMINO)-3-(2,3-XYLYLOXY)-2-PROPANOL

Systematic Name

English

xibenolol [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29576